Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Brief summary (registry, in English)

To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.

What you commit to

• Study type: Interventional · Phase 2/3
• Participants enrolled: 549
• From 18 Dec 2017 to the primary completion date, 19 Feb 2024
• 51 sites in 5 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (51)

Sites in registry order. Pick your city on the disease page to sort them by distance.